353 related articles for article (PubMed ID: 20141348)
1. A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin.
Yiu KH; Cheung BM; Tse HF
Expert Opin Investig Drugs; 2010 Mar; 19(3):437-49. PubMed ID: 20141348
[TBL] [Abstract][Full Text] [Related]
2. Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease.
Olsson AG
Expert Opin Pharmacother; 2010 Jul; 11(10):1715-26. PubMed ID: 20518616
[TBL] [Abstract][Full Text] [Related]
3. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y
Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324
[TBL] [Abstract][Full Text] [Related]
4. Safety of niacin and simvastatin combination therapy.
Bays H
Am J Cardiol; 2008 Apr; 101(8A):3B-8B. PubMed ID: 18375239
[TBL] [Abstract][Full Text] [Related]
5. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
Maccubbin D; Bays HE; Olsson AG; Elinoff V; Elis A; Mitchel Y; Sirah W; Betteridge A; Reyes R; Yu Q; Kuznetsova O; Sisk CM; Pasternak RC; Paolini JF
Int J Clin Pract; 2008 Dec; 62(12):1959-70. PubMed ID: 19166443
[TBL] [Abstract][Full Text] [Related]
6. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
[TBL] [Abstract][Full Text] [Related]
8. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms.
Dishy V; Liu F; Ebel DL; Atiee GJ; Royalty J; Reilley S; Paolini JF; Wagner JA; Lai E
J Clin Pharmacol; 2009 Apr; 49(4):416-22. PubMed ID: 19246721
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
Fazio S; Guyton JR; Polis AB; Adewale AJ; Tomassini JE; Ryan NW; Tershakovec AM
Am J Cardiol; 2010 Feb; 105(4):487-94. PubMed ID: 20152243
[TBL] [Abstract][Full Text] [Related]
10. Nicotinic acid + larodiorant. Laropiprant adds its own adverse effects.
Prescrire Int; 2010 Feb; 19(105):9-11. PubMed ID: 20455330
[TBL] [Abstract][Full Text] [Related]
11. Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders.
Vo AN; Kashyap ML
Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1303-10. PubMed ID: 19018682
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
[TBL] [Abstract][Full Text] [Related]
13. Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid.
Schima SM; Maciejewski SR; Hilleman DE; Williams MA; Mohiuddin SM
Expert Opin Pharmacother; 2010 Apr; 11(5):731-8. PubMed ID: 20210682
[TBL] [Abstract][Full Text] [Related]
14. New perspectives on the use of niacin in the treatment of lipid disorders.
McKenney J
Arch Intern Med; 2004 Apr; 164(7):697-705. PubMed ID: 15078639
[TBL] [Abstract][Full Text] [Related]
15. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
Shah S; Ceska R; Gil-Extremera B; Paolini JF; Giezek H; Vandormael K; Mao A; McCrary Sisk C; Maccubbin D
Int J Clin Pract; 2010 May; 64(6):727-38. PubMed ID: 20518948
[TBL] [Abstract][Full Text] [Related]
17. What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?
Bays HE; Ballantyne C
Curr Opin Lipidol; 2009 Dec; 20(6):467-76. PubMed ID: 19779335
[TBL] [Abstract][Full Text] [Related]
18. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
Paolini JF; Mitchel YB; Reyes R; Kher U; Lai E; Watson DJ; Norquist JM; Meehan AG; Bays HE; Davidson M; Ballantyne CM
Am J Cardiol; 2008 Mar; 101(5):625-30. PubMed ID: 18308010
[TBL] [Abstract][Full Text] [Related]
19. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
Duvall WL; Blazing MA; Saxena S; Guyton JR
J Cardiovasc Risk; 2002 Dec; 9(6):339-47. PubMed ID: 12478203
[TBL] [Abstract][Full Text] [Related]
20. Niacin use and cutaneous flushing: mechanisms and strategies for prevention.
Davidson MH
Am J Cardiol; 2008 Apr; 101(8A):14B-19B. PubMed ID: 18375236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
